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Abstract
MYC-driven lymphomas, especially those with concurrent MYC and BCL2 dysregulation, are 
currently a challenge in clinical practice due to rapid disease progression, resistance to standard 
chemotherapy and high risk of refractory disease. MYC plays a central role by coordinating 
hyperactive protein synthesis with upregulated transcription in order to support rapid proliferation 
of tumor cells. Translation initiation inhibitor rocaglates have been identified as the most potent 
drugs in MYC-driven lymphomas as they efficiently inhibit MYC expression and tumor cell 
viability. We found that this class of compounds can overcome eIF4A abundance by stabilizing 
target mRNA-eIF4A interaction that directly prevents translation. Proteome-wide quantification 
demonstrated selective repression of multiple critical oncoproteins in addition to MYC in B cell 
lymphoma including NEK2, MCL1, AURKA, PLK1, and several transcription factors that are 
generally considered undruggable. Finally, (−)-SDS-1–021, the most promising synthetic 
rocaglate, was confirmed to be highly potent as a single agent, and displayed significant synergy 
with the BCL2 inhibitor ABT199 in inhibiting tumor growth and survival in primary lymphoma 
cells in vitro and in patient-derived xenograft mouse models. Overall, our findings support the 
strategy of using rocaglates to target oncoprotein synthesis in MYC-driven lymphomas.
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Introduction
MYC aberrations including translocation and amplification are commonly observed in B cell 
lymphomas. As a result, overexpressed MYC serves as the driving force in disease 
transformation and progression(1) through differentially regulating target genes(2), as well 
as enhancing existing oncogenic pathway activities(3). While MYC rearrangements 
characterize Burkitt lymphoma (BL), they are also present in ~15% of diffuse large B cell 
lymphomas (DLBCL) and are found to be associated with inferior outcomes (4–6). Notably, 
the majority of MYC translocated DLBCL also possesses the IGH/BCL2 rearrangement(7), 
comprising the category “high-grade B-cell lymphoma with translocations involving MYC 
and BCL2 and/or BCL6” in 2016 WHO classification (double-hit or triple-hit lymphoma; 
DHL/THL)(8). Cases with concomitant overexpression of MYC and BCL2 proteins, which 
represent a larger group characterized as “immunohistochemical double-hit lymphomas” 
(double expression lymphomas, DEL)(9), appear to have a similar clinical course. Generally, 
DHL/DEL accounts for about 30% of aggressive B-cell lymphomas and is highly aggressive 
with the median overall survival ranging from less than 12 months with standard R-CHOP 
therapy (10, 11).
Given the central role MYC plays in aggressive B cell lymphomas, several strategies were 
proposed to target this “undruggable” transcription factor, such as disrupting MYC 
transcription by bromodomain (BRD)-4 inhibitors. However, early clinical data showed that 
BRD4 inhibitors failed to provide durable cytotoxic effects in human cancers as a single 
agent(12). Reversal of MYC inhibition was found among relapsed patients (13), and 
reactivation of multiple oncogenic pathways was detected in BRD4 inhibitor-resistant cells 
(14, 15). While transcription adaption and reprogramming are prone to occur during tumor 
evolution, which is largely the cause of failure for single target inhibitors, augmented protein 
synthesis following MYC activation is always required to accommodate rapid proliferation, 
and has been demonstrated to be a rate-limiting determinant of cancer development(16). As 
a result, targeting protein synthesis may provide an effective and lasting approach for 
treating MYC-driven lymphomas(17).
Translation initiation is the rate-limiting step in protein sythesis, and is tightly controlled by 
interactions of the mRNA 5’UTR with initiation factors in a cap-dependent manner, or, less 
commonly, in a cap-independent manner by internal ribosome entry site (IRES). Many 
oncogenes such as MYC and CCND1 possess complex secondary structures on the mRNA 
5’UTR which rely heavily on cap-dependent initation for efficient translation(18, 19). On 
the other hand, MYC directly induces expression of components of the eukaryotic initiation 
factor 4F (eIF4F) complex and activates the mammalian target of rapamycin (mTOR) 
signaling(20), consequently upregulating cap-dependent translation initiation(21). Therefore, 
strategies directed against translation initiation are able to disrupt both MYC expression and 
the hyperactivated translation that it causes(17).
Rocaglates, a class of natural products isolated from plants of the Aglaia genus, are currently 
the most potent class of translation initiation inhibitors that function via eIF4A and are well 
tolerated in vivo (22–25). Several rocaglates including silvestrol and rocaglamide have 
showed selective inhibition of multiple oncoproteins such as MYC and MCL1, and have 
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exhibited a remarkable cytotoxic effect on a variety of tumors both in vitro and in vivo (23, 
25–27). Herein, we identified that translation initiation inhibitors are strong candidates for 
treating MYC-driven B cell lymphomas, and demonstrated the advantage of rocaglates vs. 
mTOR inhibitors on the inhibition of MYC expression. Moreover, we studied the 
mechanism of rocaglate therapy and identified multiple B cell-related oncoproteins being 
depleted. Finally, we demonstrated the therapeutic efficacy of the most potent rocaglate 
derivative (–)-SDS-1–021 in vitro and in patient-derived xenograft (PDX) models.
Materials and Methods
Tandem mass tag based mass spectrometry (TMT-MS)
Val cells were treated with (-)-SDS-1-021 (100 nM) or vehicle control for 4 hours. Proteins 
were extracted using radioimmunoprecipitation (RIPA) assay buffer with proteinase and 
phosphatase inhibitor cocktail. Proteins from three biological replicates were labeled using 
6-plex TMT kit (Thermo Fisher Scientific, Waltham, MA, USA) according to 
manufacturer’s protocol and then pooled together and fractionated by high-pH reverse phase 
chromatography. Dried fractions were re-dissolved and run by nano-LC-MS/MS using a 2-
hour gradient on a 0.075 mm x 250 mm C18 Waters CSH column feeding into a Q-Exactive 
HF mass spectrometer (Thermo Fisher Scientific).
In vivo patient-derived xenograft
Approximately 106~5×106 DEL/DHL cells from second passage PDX were inoculated to 
the flank of 6–8 week old NSG mice (JAX lab, Bar Harbor, ME, USA). After tumor reached 
palpable size, tumor-bearing mice were separated into vehicle control group (5.2% Tween 
80/5.2% PEG400 in water) and (-)-SDS-1-021 group (0.2 mg/kg). An additional ABT199 
group (1.0 mg/kg) and a combined treatment group ((-)-SDS-1-021 0.2 mg/kg + ABT199 
1.0 mg/kg) were added for DHL model. Each group contained six mice with an equal 
number of male and female animals. Drug or vehicle was given ip daily for 10 consecutive 
days. Animals were weighted and tumor size was measured with caliper daily. Tumor 
volume was calculated as V = (W2 × L)/2. At day 10 or endpoint, mice were euthanized, and 
the tumor was isolated for further examinations.
Additional information can be found in “supplementary materials and methods”.
Results
Inhibitors targeting translation initiation exhibit high potency in MYC-driven lymphomas
To identify candidate drugs for MYC-driven lymphoma, imaging- and stroma-based drug 
screening assays utilizing 30 small molecule inhibitors targeting the major signaling 
pathways in B cell lymphoma were conducted in 11 aggressive MYC-driven B cell 
lymphoma cell lines, including three BL (Namalwa, Raji and Ramos) wild-type or with 
isogenic BCL2 expression, four DHL/DEL CJ, Val, Dohh2, U2932, and the mantle cell 
lymphoma line Sp53. Among tested inhibitors, the rocaglate silvestrol exhibited the highest 
potency across all tested cells followed by the mTOR inhibitors AZD8055 and BEZ235, the 
PI3K inhibitor PIK75, and the PLK1 inhibitor Volasertib (Figure 1A). To validate our 
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results, we performed a viability assay in three DHL cells treated with silvestrol and 
AZD8055 at various concentrations and found that although both drugs act on translation 
initiation, tested cells are much more sensitive to silvestrol (Figure 1B). Overall, our data 
suggest that targeting mRNA translation initiation is a promising strategy in MYC-driven 
lymphomas.
Rocaglates but not mTOR inhibitors efficiently repress MYC expression
We next studied the effect of translation initiation inhibitors on MYC expression, given its 
central role in MYC-driven lymphoma. mTOR complex 1 (mTORC1) is the major sensor of 
nutrition and master regulator of growth in eukaryotic cells with two primary downstream 
targets, S6 kinase 1 (S6K1) and eukaryotic translation initiation factor 4E-binding protein 1 
(4EBP1). mTORC1 promotes translation initiation by phosphorylating 4EBP1. 
Phosphorylated 4EBP1 dissociates from eIF4E thereby allowing the formation of the eIF4F 
complex. To evaluate the effect of mTOR inhibitors on MYC expression, we treated the 
DHL cell lines Val and Ros50 with both allosteric and kinase inhibitors of mTOR. As 
expected, the mTOR kinase inhibitors (TORKi) Torin1 and AZD8055 dramatically 
decreased the activity of S6K1 as shown by the phosphorylation of downstream substrate 
ribosomal protein s6 (RPS6) as well as the phosphorylation 4EBP1, whereas the allosteric 
inhibitor temsirolimus failed to completely inhibit 4EBP1. Surprisingly, the TORKis only 
marginally affected MYC expression in both cell lines, while the expression of another cap-
dependent oncoprotein MCL1 was significantly decreased (Figure 2A). To confirm these 
results, we employed the 4EBP1 mutant, 4EBP1–4A as a dominant cap-dependent 
translation initiation inhibitor(28). 4EBP1–4A carries alanine substitutions at four serine/
threonine residues and thereby prevents dissociation of 4EBP1 from eIF4E induced by 
mTORC1. Interestingly, MYC expression was unchanged upon ectopic expression of the 
doxycycline-inducible 4EBP1–4A in both DHL cells (Figure 2B). Since both TORKi- and 
4EBP1–4A repress cap-dependent translation through sequestering eIF4E, such indirect 
inhibitory effect is determined by the eIF4E/4EBP1 ratio. We then disrupted eIF4E by 
siRNA knockdown and observed a substantial decrease in MYC expression (Figure 2C) 
suggesting that excessive abundance of eIF4E may have compromised the effect of TORKi 
on cap-dependent translation. Consistent with this finding, slight to moderate suppression of 
eIF4E using increasing doses of the putative eIF4E inhibitors briciclib or 4EG-I was unable 
to efficiently repress MYC expression (Figure S1A and S1B). These data indicate that cap-
dependent translation is crucial for MYC mRNA translation. However, since eIF4E is highly 
abundant in lymphocytes and eIF4E overexpression is commonly observed in B cell 
malignancies (29), TORKi treatment is insufficient to overcome the abundance of eIF4E and 
suppress MYC expression in MYC-driven lymphomas.
In contrast, silvestrol treatment dramatically decreased MYC expression in DHL and DEL 
cells (Figure 2D) at 5 nM, and abolished MYC expression at higher biologically relevant 
concentrations. Moreover, we tested silvestrol in P493–6 cells in which MYC expression is 
tetracycline-repressible, and found low concentration of silvestrol was able to abrogate MYC 
expression comparable to doxycycline (Figure S1C). Furthermore, silvestrol exhibited more 
potent inhibition of MCL1 expression compared to TORKi, yet neither significantly 
decreased BCL2 in DHL cells (Figure 2A and 2D). The findings are consistent with the fact 
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that MCL1 has a short half-life and as such any subtle change in protein synthesis or 
degradation would greatly affect the protein level, whereas the BCL2 protein is stable with a 
half-life of approximate 20 hours (30, 31). Taken together, we demonstrated that silvestrol 
potently repressed MYC expression in all MYC deregulated B cell lymphoma lines; 
however the inhibitory effect of mTOR inhibitors was compromised due to eIF4E 
overexpression.
Rocaglate strongly inhibits the cap-dependent translation of MYC
To provide insight into the distinct impact of TORKi and rocaglates on mRNA translation, 
we performed polysome fractionation to further analyze the mRNA distribution on 
ribosomes (Figure 2E). We found that silvestrol induced stronger overall translational 
suppression than Torin1 in both Val and Ros50 cells as indicated by the elevated 80S 
monosome peak and the declined polysome peaks. We then assessed the abundance of MYC 
mRNA in each fraction and observed redistribution from actively translating polysomes to 
lighter fractions in silvestrol-treated cells (Figure 2F). Similarly, the redistribution of BCL2 
and MCL1 mRNA was more prominent upon silvestrol administration. These findings are in 
accordance with the observation that silvestrol has greater impact on protein synthesis, 
especially for MYC. Because MYC mRNA contains an IRES element in 5’UTR, which 
provides MYC translation with an alternative mode of initiation, we then sought to 
determine if both cap- and IRES-dependent translations were affected. To measure the 
activities of cap- and IRES-dependent translation respectively, we generated two dual 
luciferase reporter constructs: pURF with insertion of the IRES-deleted MYC-5’UTR 
upstream of renilla luciferase, and pURF-IRES with the addition of MYC-IRES to drive 
translation of firefly luciferase (Figure 2G). We first transfected these constructs into 293T 
cells and then treated the cells with either silvestrol or Torin1 (Figure S2). As expected, 
firefly luciferase expression was exponentially increased in pURF-IRES transfected cells. 
Both cap- and IRES-dependent translations were decreased by either silvestrol or Torin1 
treatment as indicated by renilla and firefly activity respectively. However, silvestrol 
displayed much stronger inhibition, especially for cap-dependent translation. Next, we stably 
transduced DHL cells with the dual luciferase reporters using retrovirus and observed 
similar results as those in 293T cells (Figure 2H). Particularly, with silvestrol treatment, 
renilla activity was reduced by 37% and 35% at 25 nM in Val and Ros50 cells, respectively, 
and by ~55% and ~44% at 125 nM. By contrast, firefly activity was only moderately 
decreased with silvestrol treatment and was even less affected upon Torin1 administration. 
Since 25 nM of silvestrol was sufficient to abolish MYC expression whereas even 200 nM of 
Torin1 only showed marginal effect (Figure 2A and 2D), these findings suggest that the 
potent inhibition of MYC by rocaglates is mainly mediated by the substantial repression of 
cap-dependent translation, although both cap and IRES dependent translations are 
affected(32, 33).
Rocaglates overcome eIF4A abundance
Previous studies have disclosed rocaglates as selective inhibitors of eIF4A through 
diminishing its availability in eIF4F complex (25, 26, 34, 35), however recent evidence 
demonstrated that rocaglates directly bind at the interface formed between eIF4A and 
polypurine sequences on targeted mRNA, forming a stable structure to prevent ribosome 
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scanning(36, 37). Herein, we were interested to determine through which mechanism 
rocaglates achieved efficient MYC repression in DHL/DEL. First we probed the expression 
of eIF4A in DHL/DEL cells. The eIF4A family consists of three helicases in which eIF4A1 
and eIF4A2 share high resemblance and were reported to interact with silvestrol and 
episilvestrol(38), whereas eIF4A3 is distant from these isoforms in both amino acid 
sequence and function(39). We found that eIF4A1 but not eIF4A2 is highly up-regulated in 
DHL/DEL cells as compared to normal B cells (Figure S3A). Consistently, eIF4A1 mRNA 
was found to be much more abundant than eIF4A2 (Figure S3B), and knockdown of 
eIF4A1, but not eIF4A2, had significant impact on cell viability (Figure S3C). These data 
are in accordance with the common notion that eIF4A1 is the major helicase required in 
cancers.
Next, we compared the impact of eIF4A knockdown (Figure 3A) versus rocaglate treatment 
(Figure 3B) in two aspects, eIF4A abundance in eIF4F and MYC expression. Following 
siRNA-mediated eIF4A1 knockdown, consistent with previous reports (40, 41), we observed 
a marked increase of eIF4A2 expression while eIF4A1 showed no changes to eIF4A2 
depletion (Figure 3A and 3C). m7GTP pull-down assay confirmed depletion of eIF4A1 and 
eIF4A2 in the eIF4F complex in single knockdown cells. eIF4A½ double knockdown 
significantly decreased eIF4A abundance in eIF4F complex in Ros50, however such 
reduction is not as prominent in Val (Figure 3A), as reduced eIF4A may still be more 
abundant than the relatively low level of eIF4E in this cell line (Figure S3A). Cell viability 
assay confirmed that Ros50 is more vulnerable to eIF4A depletion than Val (Figure S3C). 
We then analyzed MYC expression upon eIF4A knockdown and were surprised to find that 
the MYC protein level was only marginally decreased in these cell lines (Figure 3C). Dual 
luciferase assay revealed that eIF4A knockdown failed to induce comparable reduction of 
luciferase activity (Figure 3D) to silvestrol treatment as shown in Figure 2H. These findings 
suggest that eIF4A1 is highly abundant in MYC-driven lymphoma wherein even up to 70% 
depletion had minimal effect on MYC translation. In contrast, the abundance of eIF4A1 and 
eIF4A2 in the eIF4F complex was barely affected by a high concentration of silvestrol or (-)-
SDS-1-021, a synthetic rocaglate that is more potent as a translation inhibitor than 
silvestrol(23, 42) (Figure 3B and S4). Unlike eIF4A knockdown, rocaglates efficiently 
repressed MYC at a low concentration (Figure 2D), and had no additive effect with eIF4A 
knockdown in repressing MYC (Figure 3C). In addition, rocaglates appeared to be much 
more effective on MYC repression than hippuristanol, an ATP-competitive inhibitor of 
eIF4A which impairs its helicase function (Figure 3E). These findings suggest that the 
potent MYC suppression by rocaglates is unlikely a consequence of eIF4A depletion in 
eIF4F complex in MYC-driven lymphoma cells.
Finally, to test whether rocaglates directly alter eIF4A and MYC mRNA binding, we 
conducted native RNA immunoprecipitation (RIP). We found MYC mRNA was 
significantly enriched on eIF4A1 and eIF4A2 upon rocaglate treatment (Figure 3F), while 
the previously described rocaglate-insensitive mRNA NDUFS7 was not (37) (Figure S5), 
suggesting that the rocaglate selectively stabilized the eIF4A-MYC mRNA interface. It has 
been shown that the eIF4A-mRNA-rocaglate structure is very stable that may persist even 
after ATP hydrolysis, therefore directly prevents ribosome scanning in translation initiation 
(36, 37). Collectively, we demonstrated that eIF4A exists in excess in MYC-driven 
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lymphoma cells, and that moderate depletion is insufficient to repress MYC translation. 
Apparently, rocaglates efficiently repress MYC translation by increasing MYC mRNA 
binding to eIF4A, instead of depleting it in eIF4F complex, and therefore overcome eIF4A 
abundance.
Rocaglates repress multiple critical oncoproteins in MYC-driven lymphoma
To better characterize the translation inhibitory effect of rocaglates in DHL, we performed 
tandem mass tag-based mass spectrometry (TMT-MS) to quantitatively delineate proteome-
wide changes. In Val cells treated with (-)-SDS-1-021 for 4 hours, the total abundance of 
177 proteins was depleted more than 20% (p<0.05) (Figure 4A and S6A), among which 
multiple oncoproteins critical for B cell lymphomagenesis were identified (Figure 4A). 
Pathway enrichment analysis revealed that cell cycle and PLK1 pathway activity were 
mostly involved (Figure 4B and S6B).
Notably, the Aurora-PLK-1 pathway kinases, including NEK2, AURKA, AURKB, PLK1, 
WEE1, and CHEK1 were highly enriched in the depleted protein pool. This group of kinases 
is commonly recognized as checkpoint regulators, whereas emerging evidence revealed their 
essential role in cancer development, especially in maintaining MYC functions (43, 44). 
These data highly suggest that not only MYC expression but also its functional network was 
impaired by rocaglate treatment. In addition, we noticed that besides MYC, multiple B cell 
lymphoma-related transcription factors were also significantly decreased, including EST1, 
TCF3, BCL6, and NOTCH1, which greatly enhanced the therapeutic value of rocaglates, 
given that transcription factors are usually hard to target using small molecule inhibitors. 
Also, we examined the total (Figure S6C) and eIF4A-bound mRNA levels (Figure S5) of the 
representative depleted genes and found that most of them were up-regulated and enriched 
on eIF4A upon rocaglate treatment, suggesting that the depletion indeed resulted from 
translation inhibition. We then validated the results in four DHL/DEL cell lines and found 
that different from Torin1 treatment (Figure S6D), all of the examined oncoproteins were 
consistently depleted by silvestrol and (-)-SDS-1-021 at relatively low concentration (25 
nM) (Figure 4C). Overall, these findings suggest that rocaglates and derivatives bear great 
potential for treating MYC-driven lymphomas due to the collaborative inhibition of MYC as 
well as multiple critical B cell lymphoma-associated oncoproteins.
(-)-SDS-1-021 exhibits promising therapeutic effect, and synergizes with ABT199 in vitro 
and in vivo
As shown in Figure 2, neither TORKi nor silvestrol were able to repress BCL2 expression in 
DHL cells, likely due to its high abundance and long half-life. Therefore, we tested whether 
the addition of BCL2 inhibitor ABT199 may synergize with rocaglates for more efficient 
tumor suppression. Val and Ros50 cells were treated with silvestrol and ABT199 at various 
concentrations, individually or in combination (Figure S7A). As expect, single treatment 
induced slight-to-moderate cell death, while the combined treatment exhibited significant 
synergy and dramatically killed the lymphoma cells. Next, we found that (-)-SDS-1-021 
showed a strong inhibitory effect at a very low concentration (2.5 nM) especially in 
DHL/DEL lymphoma cells (Figure S7B, Figure 5A and 5B). Importantly, CD19-positive 
normal B cells showed relative resistance to (-)-SDS-1-021 treatment (Figure 5A), in 
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agreement with our finding that multiple lymphoma- related oncoproteins are repressed by 
rocaglates. We then employed (-)-SDS-1-021 and combination treatment in a series of 
primary DEL/DHL cells and found (-)-SDS-1-021 potently decreased cell viability whilst 
the inhibitory effect was further enhanced when combined with ABT199 (Figure 5C).
To assess the in vivo therapeutic effect, we adopted two established PDX models, one 
derived from a DEL patient and the other derived from a relapsed DHL patient. For the DEL 
model, single treatment of (-)-SDS-1-021 at a low dosage of 0.2 mg/kg was sufficient to 
abolish tumor growth and eliminated the tumor burden in these animals (Figure 5D-F). The 
DHL model exhibited more aggressive behaviors with expeditious tumor growth, blood 
vessel infiltration and local invasion. ABT199 single treatment was able to moderately delay 
tumor growth. By contrast, (-)-SDS-1-021 single treatment induced potent tumor repression 
while the combination with ABT199 almost abolished the tumor burden with only minimal 
residuals observed at the implanted site (Figure 5G-I). Morphological and 
immunohistochemical examination revealed that (-)-SDS-1-021 treatment induced massive 
cell death, substantially decreased cell proliferation and abrogation of MYC expression in 
DEL PDX model (Figure 5J). In DHL PDX model, ABT199 single treatment had no effect 
on MYC expression or proliferative index. (-)-SDS-1-021 administration substantially 
decreased MYC expression (>50% in controls vs 10% in (-)-SDS-1-021 group vs <5% in 
combination group) and ki67 index (100% in controls vs ~40% in (-)-SDS-1-021 group vs 
~20% in combination group) (Figure 5J). No significant body weight loss or emaciation was 
observed in treatment groups. These findings strongly suggest that (-)-SDS-1-021 is a 
promising therapeutic reagent which may synergize with ABT199 for the treatment of 
MYC-driven lymphomas.
Discussion
In MYC-driven lymphomas, protein synthesis is enhanced to sustain rapid proliferation 
through MYC-mediated upregulation of eIF4E, eIF4A, and eIF4G (45). Upregulated 
translation, in turn, promotes excessive production of MYC, thereby forming a feed-forward 
loop between MYC and active mRNA translation(46). As a result, targeting protein 
synthesis, especially initiation through components of the eIF4F complex, has great 
potential. Indeed, our drug screen identified translation inhibitors to exhibit the highest 
potency across tested MYC-driven lymphoma cells. However, the highly overexpressed 
eIF4F complex components in MYC-driven lymphoma, especially eIF4E and eIF4A, may 
compromise the efficacy of direct inhibitors. Consistent with previous reports (47), we 
demonstrated that overexpressed eIF4E weakened the effect of cap-dependent translation 
inhibition and sustained MYC expression upon mTOR inhibitors, bircicilib or 4EG-I 
treatment. Unlike mTOR inhibitors, rocaglates potently represses MYC translation, as 
indicated by strong inhibition of cap-dependent translation. It is interesting that targeting 
eIF4A would generate such efficient repression on MYC, as eIF4A is the most abundant 
initiation factor whereas eIF4E is the least abundant one(41, 48). In fact, we showed eIF4A 
exists in excess in DHL cells that moderate depletion may not be able to suppress MYC 
expression. Moreover, we found rocaglates did not change the total level of eIF4A or deplete 
it within eIF4F complex, instead increasing the binding of target mRNA on eIF4A. Recent 
studies have clarified rocaglates as a type of interfacial inhibitors that bind to the pocket 
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formed by eIF4A and polypurine-rich mRNA, functioning as a roadblock against 
translation(36, 37).This unique action allows rocaglates to take advantage of the overly 
abundant eIF4A in MYC-driven lymphoma thereby effectively repressing MYC and other 
target mRNA translation, meanwhile inhibitors targeting eIF4A function, e.g. hippuristanol 
and elatol, struggle to saturate the gigantic eIF4A pool and often exhibit low potency(49, 
50).
We found oncoproteins depleted by rocaglates in DHL principally consist of two major 
categories, proliferation-related kinases and transcription factors. The proliferation-related 
kinases predominantly reside in the replication checkpoint Aurora-PLK1 signaling and 
downstream targets. These kinases control the progression from G2 to M phase meanwhile 
play an important role in maintaining the stability of MYC protein (43, 44). As a result, 
rocaglates not only potently repress MYC but also simultaneously disrupt the MYC 
regulatory network, again highlighting this class of compounds as a promising candidate for 
treating MYC driven lymphomas. Transcription factors in addition to MYC, such as TCF3, 
BCL6 and NOTCH1 play crucial roles in the B cell lymphomagenesis (51–54) and were also 
substantially suppressed by rocaglate treatment. This finding implies a great therapeutic 
value in lymphoma treatment, as transcription factors usually have wide active domains that 
are unable to be targeted by small molecule inhibitors. Collectively, in light of their multi-
targeting properties, rocaglates should be considered as a broad-spectrum therapeutic agent, 
which has many virtues such as high potency and a lower likelihood for the resistance 
development.
Although rocaglates exhibited potent inhibition on MYC and other oncoproteins, BCL2, the 
hallmark anti-apoptotic protein overexpressed in DHL/DEL remains unaffected. Therefore, 
the combination of ABT199 with rocaglates showed a remarkable synergistic effect which 
may result from simultaneous inhibition of BCL2 and MCL1 according to our previous 
study (55). The combination strategy significantly decreased the effective dosage of both 
rocaglate and ABT199, and thus could minimize the toxicity of both drugs.
Finally, large scale chemical synthesis of rocaglate derivatives has been achieved recently 
(56), and hence the limited availability from natural resources (e.g. silvestrol) will no longer 
hinder potential use of this class of inhibitors. Our previous compound screen unveiled a few 
synthetic rocaglates that are especially promising including CR-1–31-B and (-)-
SDS-1-021(57–59). In the present study, a low dose (0.2 mg/kg) of (-)-SDS-1-021 is 
sufficient to induce rapid tumor regression in DHL/DEL PDX mouse models, which is 
consistent with the previous study showing high potency of this compound in multiple 
myeloma in vivo(23). Taken together, the preclinical findings presented here demonstrate 
that synthetic rocaglates are promising candidates for treating aggressive B cell lymphoma, 
especially for the most refractory type DHL/DEL. Despite silvestrol showing favorable 
pharmacokinetics in mice (60), the pharmacokinetics and pharmacodynamics of rocalgate 
derivate such as (-)-SDS-1-021 should be further characterized before they are taken into 
clinical trials.
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Figure 1. 
Inhibitors targeting protein synthesis exhibit high potency in MYC-driven lymphomas. a 
Functional drug screens in MYC-driven lymphomas (Namalwa, Raji, Ramos, Namalwa-
BCL2, Raji-BCL2, Ramos BCL2, CJ, Val, Dohh2, U2932 and Sp53). Small molecule 
inhibitors and corresponding targets are clustered according biology function and 
represented in an AUC heatmap format. AUC was calculated from concentration (μM) log-
transformed dose-response curve of three independent experiments. b mTOR inhibitor 
AZD8055 and silvestrol decreased DHL cell viability. DHL cell Dohh2, Val and Ros50 were 
treated with AZD8055 or silvestrol at various concentrations. Cell viability was determined 
by prestoblue fluorescent unit (PFU) at 48 hours and normalized to vehicle control. Data 
presented show the mean ± SD of at least 3 independent experiments.
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Figure 2. 
Rocaglates but not mTOR inhibitors efficiently repress MYC expression. a Effect of mTOR 
inhibitors on oncoprotein MYC, MCL1 and BCL2. Val and Ros50 cells treated with Torin1, 
temsirolimus (TEM) and AZD8055 at indicated concentrations for 24 hours. Protein levels 
were examined by immunoblotting. b 4EBP1–4A was introduced into Val and Ros50 cells 
by retrovirus infection and the ectopic expression was induced by doxycycline (1 μg/ml) for 
48 hours. c siRNA targeting eIF4E was transfected into Val and Ros50 cells by 
electroporation. MYC protein level was determined at 48 hours post-transfection. d DHL 
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cell lines Val and Ros50, and DEL cell lines U2932 and LY19 were treated with increasing 
concentrations of silvestrol for 24 hours. MYC, MCL1, BCL2 and PARP were measured by 
immunoblotting. e Polysome fractionations were plotted (260nM absorbance) in Val and 
Ros50 cells treated with 200nM Torin1, 125nM Silvestrol (Silv) or vehicle control for 2 
hours. Collection was set at one fraction per minute. f Distribution of MYC, MCL1 and 
BCL2 mRNA was measured in each fraction. Relative mRNA content per fraction was 
measured by RT-qPCR. g Schematic illustration describing luciferase reporters used in this 
study. pURF contains IRES element deleted MYC 5’UTR inserted proximal to renilla 
luciferase coding sequence. pURF-IRES was generated by inserting MYC-IRES element in 
front of firefly luciferase coding sequence in pURF construct. h Val and Ros50 cells 
transduced with pURF-IRES were treated with Torin1 or silvestrol (Silv) for 4 hours. 
Luciferase activity was measured and normalized to cell number and that of vehicle control. 
Data in a-e shown are representative of at least 3 independent experiments. Data presented 
in h show the mean ± SD of at least 3 independent experiments.
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Figure 3. 
Rocaglates increase MYC mRNA binding to eIF4A, instead of depleting eIF4A in eIF4F. a 
Evaluation of total eIF4A1 and eIF4A2 as well as their abundance in eIF4F following 
siRNA knockdown in Val and Ros50 cells. Knockdown efficiency indicated in lane. b 
Evaluation of eIF4A1 and eIF4A2 abundance in eIF4F after 4 hours treatment with 125nM 
silvestrol (Silv), 100 nM (-)-SDS-1-021(SDS) or vehicle control in Val and Ros50 cells. c 
Alterations of MYC expression after eIF4A1, eIF4A2 or combined knockdown, and with 
silvestrol added. siRNA transfected Val and Ros50 cells were incubated with vehicle control 
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or silvestrol (125 nM) for 4 hours. d Dual luciferase assay performed in eIF4A knock down 
cells. Luciferase activity measured at 48 hours post-transfection and normalized to cell 
number. e eIF4A inhibitor hippuristanol (Hipp) and (−)SDS-1–021 (SDS)(24 hours) induced 
reduction of MYC protein. f Native RNA immunoprecipitation measuring MYC mRNA 
enrichment on eIF4A1 and eIF4A2. Data shown in a, b, c and e are representative of at least 
3 independent experiments. Data presented in d and f show the mean ± SD of at least 3 
independent experiments.
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Figure 4. 
Rocaglates repress multiple critical oncoproteins in DHL/DEL. a Quantitative proteomics 
demonstrating the impact of (-)-SDS-1-021 treatment (100 nM) relative to vehicle control in 
Val cells after 4-hour incubation (three biological replicates TMT labelled). Totally, 6385 
proteins were identified, of which 177 were significantly depleted for more than 20% by (-)-
SDS-1-021 (P < 0.05). Depleted critical oncoproteins in B cell lymphoma are highlighted 
and presented as heatmap (log2 transformation of relative abundance ratio). b Enriched 
pathways identified by querying the 177 depleted proteins in MSigDB C2 canonical 
pathway database. c Val, Ros50, U2904 and Carnaval cells were treated with vehicle control, 
silvestrol (25nM) or (-)-SDS-1-021 (25nM) for 24 hours and validated the expression of the 
target oncoproteins by immunoblotting. Data shown are representative of at least 3 
independent experiments.
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Figure 5. 
(-)-SDS-1-021 exhibits promising therapeutic effect, and synergizes with ABT199 in vitro 
and in vivo. a Impact of (-)-SDS-1-021(SDS) on normal CD19+ B cell and DHL/DEL cell 
viability at 48 hours. PFU in treated cells was normalized to vehicle control. b Impact of (-)-
SDS-1-021(SDS) on DHL/DEL cell proliferation. PFU in treatment groups was normalized 
to day 0. c Efficacy of (-)-SDS-1-021, ABT199 (50 nM) and combined treatment (2.5nM 
SDS+ 50 nM ABT199) in primary DEL/DHL lymphoma cells. PFU was normalized to day 
0. Combination index (CI) is calculated and indicated as the value less than 1 suggesting 
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synergistic effect between two drugs. d Tumor growth of a double expression lymphoma 
(DEL) model in NSG mice. (-)-SDS-1-021(0.2mg/kg) or vehicle control was administered 
by intraperitoneal (i.p.) injections daily for 10 days. e Weight of tumor from vehicle control 
or (-)-SDS-1-021 treated DEL PDX mice at endpoint. P<0.0001. f Representative images of 
the tumors from DEL PDX therapeutic study shown in d and e. g Tumor growth of double 
hit lymphoma (DHL) in NSG mice. (-)-SDS-1-021(0.2 mg/kg), ABT199 (1 mg/kg), 
combined treatment or vehicle control was administered by i.p. injections daily for 10 days. 
h Weight of tumor from vehicle control or therapeutic groups DHL PDX mice at endpoint. P 
value between combined and control group (P <0.0001), ABT199 group (P =0.0013), or (-)-
SDS-1-021 group, (P =0.0019). i Representative images of the tumors from DHL PDX 
therapeutic study shown in g and h. j IHC staining of MYC and Ki67 in DEL and DHL 
PDX models. Original magnification ×200. Data shown in a-c represent mean ± SD of at 
least 3 independent experiment. Results are shown as mean ± SD of 6 animals/group for d 
and g.
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